查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971853

大麻素藥物發現與開發市場分析及預測（至2035年）：按類型、產品、服務、技術、應用、形式、最終用戶、階段、模式和功能分類

Cannabinoid Based Drug Discovery And Development Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Form, End User, Stage, Mode, Functionality
出版日期: | 出版商: Global Insight Services | 英文 408 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，大麻素藥物研發市場規模將從2024年的17.6億美元成長至22.8億美元，年複合成長率約為2.6%。該市場涵蓋針對多種疾病的大麻素衍生藥物的研究與開發。借助生物技術的進步，該市場探索大麻化合物的治療潛力，重點關注疼痛管理、神經系統疾病和腫瘤治療。不斷變化的法規環境和人們對大麻治療方法的日益認可正在推動創新，臨床試驗和安全性評估也日益受到重視，以滿足嚴格的醫療標準。

受治療應用相關研發投入不斷成長的推動，大麻素藥物發現和開發市場正經歷強勁成長。製藥領域處於領先地位，這主要得益於人們對大麻素療法在疼痛管理和神經系統疾病治療方面日益成長的興趣。在該領域，合成大麻素憑藉其可控制的成分和可預測的療效，佔據主導地位。天然大麻素是成長第二快的細分市場，反映出人們對植物來源化合物的偏好日益增強。研發服務領域也展現出良好的成長前景，受託研究機構（CRO）在推動大麻素研究方面發揮著至關重要的作用。由於需要全面的安全性和有效性數據，臨床前研究服務處於主導地位。臨床試驗服務是成長第二快的領域，這得益於大麻素療法監管核准的不斷增加。對奈米技術和經皮吸收貼片創新給藥系統的投資進一步提升了市場潛力，並有望提高相關人員的盈利。

市場區隔
類型 合成大麻素，天然大麻素
產品 大麻二酚（CBD）、四氫大麻酚（THC）、大麻醇（CBG）、大麻酚（CBN）、大麻色烯（CBC）
服務 臨床前研究、臨床試驗、法規諮詢、藥物製劑。
科技 高效液相層析（HPLC）、氣相層析法（GC）、質譜法（MS）、核磁共振法（NMR）
目的 疼痛管理、神經系統疾病、腫瘤學、精神疾病
形式 片劑、膠囊、油劑、乳霜、吸入劑
最終用戶 製藥公司、研究機構、受託研究機構
步 藥物發現、臨床前試驗、I期臨床試驗、II期臨床試驗、III期臨床試驗
模式 內部開發，外包開發
功能 鎮痛、抗發炎、抗驚厥、神經保護。

市場概況：

大麻素藥物研發市場正經歷市場佔有率、定價策略和新產品上市方面的動態變化。各公司正利用創新製劑技術和策略聯盟來鞏固其市場地位。定價策略競爭日益激烈，反映出需要在價格可負擔性和尖端研發成本之間取得平衡。在新興市場，隨著監管環境的改善和大麻素療法分銷管道的擴大，產品上市數量激增。這種環境為成長和創新提供了理想的條件。市場競爭日趨激烈，主要企業正憑藉先進的研發能力和多元化的產品系列爭奪主導。監管影響至關重要，北美和歐洲嚴格的監管準則為產品核可和市場准入設定了高標準。與競爭對手的基準分析顯示，臨床試驗和專利收購的投資趨勢正在上升。該市場的特點是技術快速發展，因此，企業必須在創新和合規方面領先，才能維持競爭優勢。

主要趨勢和促進因素：

受監管環境不斷變化和大麻素療法接受度日益提高的推動，大麻素藥物的發現和開發市場正經歷強勁成長。主要趨勢包括：從慢性疼痛管理到神經系統疾病等眾多醫學領域，大麻素臨床試驗的數量都在增加。製藥業正經歷戰略合作和聯合研究的激增，旨在加速藥物的發現和開發。推動這一成長的關鍵因素是對大麻素治療潛力的日益認可，這促使研發投入不斷增加。此外，生物技術和基因組學的進步使得大麻素藥物的標靶化和製劑更加精準，進一步強化了這一趨勢。各地合法化進程的推進正在擴大市場進入，並推動對創新治療方法的需求。此外，隨著慢性病盛行率的上升和人口老化，人們對新的治療方案的需求日益成長，而大麻素被視為一種極具前景的替代療法。對於能夠駕馭複雜的法規環境並提供有效、安全且合規的大麻素治療方法的公司而言，存在著許多機會。隨著市場日趨成熟，預計將有巨大的成長潛力，尤其是在醫療基礎設施仍在發展的新興市場。

抑制因素和挑戰：

市場面臨諸多重大限制與挑戰。監管障礙仍然是主要障礙，各國不同的法律體制使研發工作變得複雜。這種不一致會延緩醫藥品認證過程並增加合規成本。此外，圍繞大麻衍生產品的偏見依然存在，影響著大眾認知和投資者信心。這種偏見會阻礙潛在的合作關係和資金籌措機會。另外，人體內大麻素交互作用的複雜性需要精密的調查方法，這需要投入大量的時間和資源。智慧財產權問題也是一大挑戰；現有專利的密集佈局可能導致法律糾紛並阻礙創新。最後，市場也面臨供應鏈限制，尤其是在採購高品質原料方面，這會影響生產計劃和成本結構。總而言之，這些挑戰阻礙了市場成長和更廣泛的接受度。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 合成大麻素
    • 天然大麻素
  • 市場規模及預測：依產品分類
    • 大麻二酚（CBD）
    • 四氫大麻酚（THC）
    • 大麻酚（CBG）
    • 大麻酚（CBN）
    • 大麻鉻（CBC）
  • 市場規模及預測：依服務分類
    • 臨床前研究
    • 臨床試驗
    • 監理諮詢
    • 藥物製劑
  • 市場規模及預測：依技術分類
    • 高效液相層析（HPLC）
    • 氣相層析法（GC）
    • 質譜（MS）
    • 核磁共振（NMR）
  • 市場規模及預測：依應用領域分類
    • 疼痛管理
    • 神經系統疾病
    • 腫瘤學
    • 精神疾病
  • 市場規模及預測：依類型
    • 藥片
    • 膠囊
    • 油
    • 奶油
    • 吸入器
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 研究機構
    • 受託研究機構
  • 市場規模及預測：依階段分類
    • 藥物發現
    • 臨床前
    • 第一階段
    • 第二階段
    • 第三階段
  • 市場規模及預測：按模式
    • 內部開發
    • 外包
  • 市場規模及預測：依功能分類
    • 緩解疼痛
    • 消炎（藥）
    • 抗驚厥藥
    • 神經保護

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • GW Pharmaceuticals
  • Corbus Pharmaceuticals
  • Zynerba Pharmaceuticals
  • Cara Therapeutics
  • InMed Pharmaceuticals
  • Tetra Bio-Pharma
  • Kalytera Therapeutics
  • Axim Biotechnologies
  • Emerald Health Pharmaceuticals
  • Vitality Biopharma
  • RespireRx Pharmaceuticals
  • CannbioRx Life Sciences
  • Ananda Scientific
  • Cardiol Therapeutics
  • Skylight Health Group
  • Medipharm Labs
  • Avicanna
  • PharmaCielo
  • The Valens Company
  • Lexaria Bioscience

第9章 關於我們

簡介目錄
Product Code: GIS33062

Cannabinoid Based Drug Discovery And Development Market is anticipated to expand from $1.76 billion in 2024 to $2.28 billion by 2034, growing at a CAGR of approximately 2.6%. The Cannabinoid Based Drug Discovery And Development Market encompasses the research and creation of pharmaceuticals derived from cannabinoids, targeting various medical conditions. This market leverages advancements in biotechnology to explore therapeutic potentials of cannabis compounds, focusing on pain management, neurological disorders, and oncology. Regulatory shifts and increasing acceptance of cannabis-based treatments propel innovation, with a strong emphasis on clinical trials and safety assessments to meet stringent medical standards.

The Cannabinoid Based Drug Discovery And Development Market is experiencing robust growth, propelled by increased research into therapeutic applications. The pharmaceuticals segment is at the forefront, driven by rising interest in cannabinoid-based therapeutics for pain management and neurological disorders. Within this segment, synthetic cannabinoids are the top performers due to their controlled composition and predictable effects. Natural cannabinoids follow as the second highest performing sub-segment, reflecting a growing preference for plant-derived compounds. The research and development services segment also shows promising growth, with contract research organizations (CROs) playing a pivotal role in advancing cannabinoid research. Preclinical research services are leading, driven by the need for comprehensive safety and efficacy data. Clinical trials services are the second most dynamic sub-segment, supported by increased regulatory approvals for cannabinoid-based treatments. Investment in innovative delivery systems, such as nanotechnology and transdermal patches, further enhances market potential, indicating a lucrative trajectory for stakeholders.

Market Segmentation
TypeSynthetic Cannabinoids, Natural Cannabinoids
ProductCannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC)
ServicesPreclinical Research, Clinical Trials, Regulatory Consulting, Drug Formulation
TechnologyHigh-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR)
ApplicationPain Management, Neurological Disorders, Oncology, Psychiatric Disorders
FormTablets, Capsules, Oils, Creams, Inhalers
End UserPharmaceutical Companies, Research Institutes, Contract Research Organizations
StageDiscovery, Preclinical, Phase I, Phase II, Phase III
ModeIn-House, Outsourced
FunctionalityAnalgesic, Anti-inflammatory, Anti-convulsant, Neuroprotective

Market Snapshot:

The Cannabinoid Based Drug Discovery and Development Market is witnessing dynamic shifts in market share, pricing strategies, and new product launches. Companies are leveraging innovative formulations and strategic partnerships to enhance their market positions. Pricing strategies are increasingly competitive, reflecting the need to balance affordability with cutting-edge research and development costs. Emerging markets are seeing a surge in product launches as regulatory landscapes become more favorable, allowing for a wider distribution of cannabinoid-based therapeutics. This environment fosters a landscape ripe for growth and innovation. Competition in the market is intense, with key players vying for dominance through advanced research capabilities and diversified product portfolios. Regulatory influences play a critical role, with stringent guidelines in North America and Europe setting high standards for product approval and market entry. Benchmarking against competitors reveals a trend towards increased investment in clinical trials and patent acquisitions. The market is characterized by rapid technological advancements, making it imperative for companies to stay ahead in innovation and regulatory compliance to maintain competitive advantage.

Geographical Overview:

The cannabinoid-based drug discovery and development market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads the charge, driven by progressive legalization policies and substantial investments in research and development. The region's robust pharmaceutical infrastructure and consumer acceptance further accelerate market expansion. Europe follows with strong regulatory support and a growing focus on cannabinoid therapeutics for chronic conditions. The region's commitment to innovation and clinical trials enhances its market potential. In the Asia Pacific, the market is burgeoning, propelled by increasing awareness and investments in cannabinoid research. Countries like Australia and China are emerging as key players, leveraging scientific advancements and supportive regulations. Latin America and the Middle East & Africa are nascent markets with promising prospects. In Latin America, countries like Colombia are capitalizing on favorable climates for cannabis cultivation. Meanwhile, the Middle East & Africa are gradually recognizing the medicinal potential of cannabinoids, driving future growth.

Key Trends and Drivers:

The Cannabinoid Based Drug Discovery And Development Market is experiencing robust growth due to evolving regulatory landscapes and increasing acceptance of cannabinoid-based therapeutics. Key trends include the rise in clinical trials exploring cannabinoids for a wide range of medical conditions, from chronic pain management to neurological disorders. The pharmaceutical industry is witnessing a surge in strategic partnerships and collaborations aimed at accelerating drug discovery and development processes. A significant driver is the growing awareness of cannabinoids' therapeutic potential, which is spurring investment in research and development. This is further bolstered by advancements in biotechnology and genomics, enabling more precise targeting and formulation of cannabinoid-based drugs. Legalization efforts across various regions are expanding market access and fueling demand for innovative treatments. Additionally, the increasing prevalence of chronic diseases and an aging population are intensifying the need for novel therapeutic options, positioning cannabinoids as a promising alternative. Opportunities abound for companies that can navigate the complex regulatory environment and deliver effective, safe, and compliant cannabinoid-based therapies. As the market matures, there is potential for substantial growth, particularly in emerging markets with evolving healthcare infrastructures.

Restraints and Challenges:

The cannabinoid-based drug discovery and development market faces several notable restraints and challenges. Regulatory hurdles remain a significant barrier, as varying legal frameworks across countries complicate research and development efforts. This inconsistency can delay drug approval processes and increase compliance costs. Additionally, the stigma surrounding cannabis-derived products persists, affecting public perception and investor confidence. This stigma can deter potential partnerships and funding opportunities. Furthermore, the complexity of cannabinoid interactions within the human body requires sophisticated research methodologies, demanding substantial investment in time and resources. Intellectual property issues also pose challenges, as the dense landscape of existing patents can lead to legal disputes and hinder innovation. Lastly, the market grapples with supply chain constraints, particularly in sourcing high-quality raw materials, which can impact production timelines and cost structures. These challenges collectively impede the market's growth and potential for broader acceptance.

Key Players:

GW Pharmaceuticals, Corbus Pharmaceuticals, Zynerba Pharmaceuticals, Cara Therapeutics, InMed Pharmaceuticals, Tetra Bio-Pharma, Kalytera Therapeutics, Axim Biotechnologies, Emerald Health Pharmaceuticals, Vitality Biopharma, RespireRx Pharmaceuticals, CannbioRx Life Sciences, Ananda Scientific, Cardiol Therapeutics, Skylight Health Group, Medipharm Labs, Avicanna, PharmaCielo, The Valens Company, Lexaria Bioscience

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Mode
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Synthetic Cannabinoids
    • 4.1.2 Natural Cannabinoids
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cannabidiol (CBD)
    • 4.2.2 Tetrahydrocannabinol (THC)
    • 4.2.3 Cannabigerol (CBG)
    • 4.2.4 Cannabinol (CBN)
    • 4.2.5 Cannabichromene (CBC)
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Preclinical Research
    • 4.3.2 Clinical Trials
    • 4.3.3 Regulatory Consulting
    • 4.3.4 Drug Formulation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 High-Performance Liquid Chromatography (HPLC)
    • 4.4.2 Gas Chromatography (GC)
    • 4.4.3 Mass Spectrometry (MS)
    • 4.4.4 Nuclear Magnetic Resonance (NMR)
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Pain Management
    • 4.5.2 Neurological Disorders
    • 4.5.3 Oncology
    • 4.5.4 Psychiatric Disorders
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Tablets
    • 4.6.2 Capsules
    • 4.6.3 Oils
    • 4.6.4 Creams
    • 4.6.5 Inhalers
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Research Institutes
    • 4.7.3 Contract Research Organizations
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical
    • 4.8.3 Phase I
    • 4.8.4 Phase II
    • 4.8.5 Phase III
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 In-House
    • 4.9.2 Outsourced
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Analgesic
    • 4.10.2 Anti-inflammatory
    • 4.10.3 Anti-convulsant
    • 4.10.4 Neuroprotective

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Form
      • 5.2.1.7 End User
      • 5.2.1.8 Stage
      • 5.2.1.9 Mode
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Form
      • 5.2.2.7 End User
      • 5.2.2.8 Stage
      • 5.2.2.9 Mode
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Form
      • 5.2.3.7 End User
      • 5.2.3.8 Stage
      • 5.2.3.9 Mode
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Form
      • 5.3.1.7 End User
      • 5.3.1.8 Stage
      • 5.3.1.9 Mode
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Form
      • 5.3.2.7 End User
      • 5.3.2.8 Stage
      • 5.3.2.9 Mode
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Form
      • 5.3.3.7 End User
      • 5.3.3.8 Stage
      • 5.3.3.9 Mode
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Form
      • 5.4.1.7 End User
      • 5.4.1.8 Stage
      • 5.4.1.9 Mode
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Form
      • 5.4.2.7 End User
      • 5.4.2.8 Stage
      • 5.4.2.9 Mode
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Form
      • 5.4.3.7 End User
      • 5.4.3.8 Stage
      • 5.4.3.9 Mode
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Form
      • 5.4.4.7 End User
      • 5.4.4.8 Stage
      • 5.4.4.9 Mode
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Form
      • 5.4.5.7 End User
      • 5.4.5.8 Stage
      • 5.4.5.9 Mode
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Form
      • 5.4.6.7 End User
      • 5.4.6.8 Stage
      • 5.4.6.9 Mode
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Form
      • 5.4.7.7 End User
      • 5.4.7.8 Stage
      • 5.4.7.9 Mode
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Form
      • 5.5.1.7 End User
      • 5.5.1.8 Stage
      • 5.5.1.9 Mode
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Form
      • 5.5.2.7 End User
      • 5.5.2.8 Stage
      • 5.5.2.9 Mode
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Form
      • 5.5.3.7 End User
      • 5.5.3.8 Stage
      • 5.5.3.9 Mode
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Form
      • 5.5.4.7 End User
      • 5.5.4.8 Stage
      • 5.5.4.9 Mode
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Form
      • 5.5.5.7 End User
      • 5.5.5.8 Stage
      • 5.5.5.9 Mode
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Form
      • 5.5.6.7 End User
      • 5.5.6.8 Stage
      • 5.5.6.9 Mode
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Form
      • 5.6.1.7 End User
      • 5.6.1.8 Stage
      • 5.6.1.9 Mode
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Form
      • 5.6.2.7 End User
      • 5.6.2.8 Stage
      • 5.6.2.9 Mode
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Form
      • 5.6.3.7 End User
      • 5.6.3.8 Stage
      • 5.6.3.9 Mode
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Form
      • 5.6.4.7 End User
      • 5.6.4.8 Stage
      • 5.6.4.9 Mode
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Form
      • 5.6.5.7 End User
      • 5.6.5.8 Stage
      • 5.6.5.9 Mode
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 GW Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Corbus Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Zynerba Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cara Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 InMed Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Tetra Bio-Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Kalytera Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Axim Biotechnologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Emerald Health Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Vitality Biopharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 RespireRx Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 CannbioRx Life Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Ananda Scientific
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cardiol Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Skylight Health Group
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Medipharm Labs
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Avicanna
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 PharmaCielo
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 The Valens Company
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Lexaria Bioscience
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us